Therapy of anal cancer

: The primary non-invasive treatment of anal-carcinoma by radiochemotherapy (RCT) is generally accepted although prospective randomised trials have not been finished yet. Finally the complex interaction of the radiotherapy and the commonly used cytotoxic agents 5-FU and Mitomycin-C are unknown, besides the radiosensitization. In the radiotherapy quality assurance is warranted in different radiotherapy-techniques and the total and single doses are well established for primary tumor (50-55 Gy) and lymphatic pathways (40-50 Gy) with 1,8 Gy single dose per fraction. According to the slow tumor regression restaging is made three months after completion of RCT. Residual tumor needs abdomino-perineal-resection.